MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s12879-026-13681-0

Медицинская библиотека · BMC infectious diseases · 2026

Design and validation of revised medication assessment tool for community-acquired Pneumonia: rMAT-CAP.

Elnajjar Sahar, Harun Sabariah Noor, Beshir Semira, Qureshi Ali, Hamed Dujana Al, Jaghoub Hebah Al, Subbah Hamzeh Al, Khowaja Danish

СтатьяВалидационное исследованиеПеревод в очереди

Аннотация

BACKGROUND

Evaluating therapeutic appropriateness is a cornerstone of antimicrobial stewardship. The original Medication Assessment Tool for Community-Acquired Pneumonia (MAT-CAP), developed in Norway, requires adaptation to account for evolving IDSA/ATS recommendations and region-specific antimicrobial resistance patterns in the UAE. To revise, adapt, and validate a Medication Assessment Tool for Community-Acquired Pneumonia (rMAT-CAP), adapted to the UAE healthcare context.

METHODS

A methodological study was conducted in three phases: (1) systematic revision of MAT-CAP indicators in accordance with 2019 IDSA/ATS guidelines and UAE resistance data; (2) content validation through a multidisciplinary Delphi panel of 10 experts; and (3) psychometric validation using inter-rater reliability and criterion validity assessments based on 30 anonymized CAP cases.

RESULTS

The rMAT-CAP comprised 13 explicit, guideline-aligned criteria covering empirical therapy, microbiological diagnostics, dose adjustment, IV-to-oral switch, and treatment duration. Content validity indices were excellent (mean I-CVI = 0.95; S-CVI/Ave = 0.95). Inter-rater reliability demonstrated almost perfect agreement for the drug domain (κ = 0.87; absolute agreement 90.0%, 95% CI: 73.5-97.9%), substantial agreement for the dose domain (κ = 0.64; absolute agreement 73.3%, 95% CI: 54.1-86.6%), and moderate agreement for the duration domain (κ = 0.45; absolute agreement 80.0%, 95% CI: 61.4-91.1%). Criterion validity showed strong diagnostic performance: sensitivity 100% (95% CI: 83.9-100%), specificity 62.5% (95% CI: 30.6-86.3%), PPV 88.0% (95% CI: 69.0-96.7%), NPV 100% (95% CI: 56.6-100%), and overall accuracy 90.0% (95% CI: 73.5-97.9%).

CONCLUSION

The rMAT-CAP is a valid, reliable, and contextually relevant tool for evaluating therapeutic appropriateness in CAP management. Its structured approach supports antimicrobial stewardship initiatives and facilitates standardized audit and feedback in UAE hospitals.

TRIAL REGISTRATION: Clinical trial number: not applicable.

Для цитирования: Elnajjar Sahar, Harun Sabariah Noor, Beshir Semira, Qureshi Ali, Hamed Dujana Al, Jaghoub Hebah Al, Subbah Hamzeh Al, Khowaja Danish. Design and validation of revised medication assessment tool for community-acquired Pneumonia: rMAT-CAP.. BMC infectious diseases. 2026. DOI: 10.1186/s12879-026-13681-0.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.